Adverse effects: 2. Extrapyramidal ‐ akathisia · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes adverse effects: Extrapyramidal effects ‐ akathisia ‐ short term (up… compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Leaving the study early ‐ short term ‐ due to lack of efficacy · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early: inefficacy ‐ short term (up to 12 weeks) compared with OLANZAPINE (very low certainty).
1 finding from 1 review
Cost‐effectiveness (long term) ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important change in life skills (long term) ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (long term) ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Extrapyramidal effects ‐ concomitant anticholinergic medication ‐ short term (up to 12 weeks) Participants requiring concomitant anticholinergic medication · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes adverse effects: Extrapyramidal effects ‐ concomitant… compared with AMISULPRIDE (very low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ any reason ‐ short term (up to 12 weeks) compared with AMISULPRIDE (very low certainty).
1 finding from 1 review
Cost‐effectiveness · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important response (defined by study) ‐ short term (up to 12 weeks) decreased rate of BPRS score < 20% · patients with schizophrenia
It is very uncertain whether FLUPHENAZINE (ORAL) changes clinically important response (defined by study) ‐ short term (up to… compared with RISPERIDONE (very low certainty).
1 finding from 1 review
Relapse ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Oral health: Not brushing teeth twice a day · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per NIMH 1987, or with…
The review found no eligible studies for this question.
1 finding from 1 review
Oral health: Not having seen a dentist in the past year · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per NIMH 1987, or with…
The review found no eligible studies for this question.
1 finding from 1 review
Global state: needing additional medication (sedation with chloral hydrate or a barbiturate > 5 times) ‐ medium term · patients with schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) showed no clear difference in global state: needing additional medication (sedation with chloral… compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (low certainty).
1 finding from 1 review
Global state: needing additional medication (sedation with chloral hydrate or a barbiturate > 5 times) ‐ medium term · schizophrenia
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related ‐ long term It is unclear how adverse events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related ‐ long term It is… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ weight increase ‐ long term It is unclear… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse events: Nervous system disorders (inc. EPS) ‐ long term It is unclear how adverse events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Nervous system disorders (inc. EPS) ‐ long term It… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ short term compared with ORAL RISPERIDONE (moderate certainty).
1 finding from 1 review